|M10290||BMS-1166||BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1.|
|M10288||BMS-1001||BMS-1001 is a potent PD-1/PD-L1 interaction inhibitor.|
|M9416||Durvalumab||Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.|
|M8959||PD1-PDL1 inhibitor 1||PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM.|
|M6102||Pembrolizumab||Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.|
|M6101||Atezolizumab||Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.|
|M6100||Nivolumab||Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.|
|M5144||BMS202||BMS202 (PD-1/PD-L1 inhibitor 2) is a inhibitor of the PD-1 (Programmed death- 1) /PD-L1 (Programmed death-ligand 1) protein/protein interaction with IC50 value of 18 nM.|
|M3813||Avelumab (MSB0010718C)||Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.